Ontology highlight
ABSTRACT: Background
Androgen receptor signaling inhibitors (ARSis) abiraterone acetate (AA) plus prednisone and enzalutamide (Enza), are currently the most administered first-line treatments for metastatic castration-resistant prostate cancer (mCRPC). AA and Enza have shown similar overall survival (OS) benefits and there is no consensus upon the best option for mCRPC first-line treatment. Volume of disease may represent a useful biomarker to predict response to therapy in such patients.Objectives
In this study, we seek to evaluate the impact of volume of disease on patients treated with first-line AA versus Enza for mCRPC.Design and methods
We retrospectively evaluated a cohort of consecutive patients with mCRPC categorized by volume of disease [high volume (HV) or l
SUBMITTER: Nuzzo PV
PROVIDER: S-EPMC9989439 | biostudies-literature | 2023
REPOSITORIES: biostudies-literature